NICE no for Opdivo in urothelial carcinoma

20th October 2017 Uncategorised 0

The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

More: NICE no for Opdivo in urothelial carcinoma
Source: News